Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
In this episode of Speaking of Urology®, Laura Bukavina, MD, MPH, and Kyle Rose, MD, discuss some of the notable abstracts that were presented at the American Society of Clinical Oncology (ASCO) Gastrourinary (GU) Cancers Symposium, which was held January 16-18, 2023 in San Francisco, California. Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Rose is a urologic oncology fellow at Moffitt Cancer Center in Tampa, Florida.
This recap was originally presented by Dr. Bukavina and Dr. Rose during the inaugural live Twitter Spaces event held by Urology Times. In the discussion, Bukavina and Rose touched on the following abstracts:
Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.